Interestingly, in a small-sample-size study of primary and metastatic tumors from four patients with CRC, SALL3 was identified as one of seventeen genes significantly upregulated in CD133+ cells as compared to CD133− CRC cells, suggesting its potential as a biomarker of CRC stemness [165]. The gene discussed is SALL3; the disease is colorectal carcinoma.